Table 1 Baseline characteristics of study participants in the piroxicam (PRX) and the placebo (PLC) groups
Variable | Categories | PRX (n = 35) | PLC (n = 35) | P-Value |
|---|---|---|---|---|
Age | Mean ± SD | 32.66 (10.30) | 33.4 (9.95) | 0.76 |
Median | 33 | 32 | ||
(Min- Max) | (19—60) | (18—60) | ||
Sex | Males [n (%)] | 10 (28.6) | 17 (48.6) | 0.086 |
Females [n (%)] | 25 (71.4) | 18 (51.4) | ||
Molar Type | 1st [n (%)] | 26 (74.3) | 25 (71.4) | 0.788 |
2nd [n (%)] | 9 (25.7) | 10 (28.6) | ||
Number of canals | 3 [n (%)] | 30 (85.7) | 25 (82.9) | 0.743 |
4 [n (%)] | 5 (14.3) | 10 (17.1) | ||
Periapical lesion size | 0-2 mm [n (%)] | 20 (57.1) | 21 (60.0) | 0.143 |
> 2-5 mm [n (%)] | 15 (42.9) | 14 (40.0) | ||
Last food intake | ≥ 8 h (Fast) [n (%)] | 14 (40.0) | 13 (37.1) | 0.806 |
< 8 h (Ate) [n (%)] | 21 (60.0) | 22 (62.9) | ||
MDAS | ≥ 12 (Anxious) [n (%)] < 12 (Calm) [n (%)] | 22 (62.9) 13 (37.1) | 16 (45.7) 19 (54.3) | 0.150 |